Review: The CRISPR’s Therapeutical revolution

21/01/2015 - 4 minutes

Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex CRISPR-Cas9 (CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR associated nuclease). “Resistance is acquired by incorporating short stretches of invading DNA sequences in genomic CRISPR loci ” Brouns, S. J. J., et al. (2008). The CRISPR repeat sequence has been discovered in 1987 but the function remained unknown for the next 20 years. The CRISPR-Cas9 system is an adaptive, heritable defense system that prokaryotes (bacteria and archaea) use to protect themselves by degrading foreign invaders’ nucleic acids such as viruses. Recently, these RNA- guided Cas9 nucleases derived from CRISPR/Cas systems have shown promise in transforming our ability to edit mammalian genomes and developing new treatments.

I/ Structural characteristics

CRISPR consists of an RNA, partly constant with a palindrome, tied to a crRNA sequence DNA specific to a target, and a Cas9 protein (Figure 1). The short guide RNA directs Cas9 to a specific genomic sequence where it induces double-strand breaks that, when imperfectly repaired, yield mutations. Cas9 can also catalyze gene replacement through homologous recombination.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member